Catheter Related Bloodstream Infection Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Treatment Type (Anti-microbial Agents and Antibiotic Lock Therapy), By Source of Infection (Coagulase-negative Staphylococcus, S. Aureus, Enteric Gram-negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), By Region and Competition, 2020-2030F

Market Overview

Global Catheter Related Bloodstream Infection Market was valued at USD 1.62 Billion in 2024 and is expected to reach USD 2.25 Billion by 2030 with a CAGR of 5.62% during the forecast period. The global Catheter Related Bloodstream Infection market is primarily driven by the increasing prevalence of hospital-acquired infections, particularly those associated with central venous catheters. Catheter related bloodstream infections are among the most frequent and serious complications of central venous catheter use, leading to significant morbidity, mortality, and healthcare costs. The rising incidence of bloodstream infections, especially in high-risk groups like immunocompromised patients undergoing treatments such as chemotherapy, further fuels market growth. The growing concern over antibiotic resistance, which complicates the treatment of catheter related bloodstream infections, has led to a rising demand for advanced diagnostic tools and infection prevention strategies. These combined factors are contributing to the expansion of the global Catheter Related Bloodstream Infection market.

Key Market Drivers

Increasing Prevalence of Hospital-Acquired Infections

Hospital-acquired infections (HAIs) are one of the most significant health concerns in medical settings globally. Catheter-related bloodstream infections (CRBSIs) are one of the leading types of HAIs, and their rising prevalence plays a substantial role in driving the growth of the global Catheter Related Bloodstream Infection market. These infections occur when pathogens enter the bloodstream through central venous catheters, a common medical device used for administering medications, fluids, and nutrients to critically ill patients. The growing number of patients requiring invasive procedures such as surgeries, dialysis, and long-term intravenous treatments leads to an increase in catheter usage, thus elevating the risk of CRBSIs. This, in turn, results in an increased demand for effective infection prevention and diagnostic solutions. According to WHO, On average, approximately 1 in 10 patients experiences healthcare-associated infections (HAIs); however, the incidence is notably higher in low- and middle-income countries, as well as among high-risk patients, such as those in intensive care units. According to a 2023 study by Balasubramanian et al., around 136 million cases of healthcare-associated antibiotic-resistant infections occur globally each year. In Europe, the impact of the six most common HAIs was found to be twice as significant as the combined burden of 32 other infectious diseases, in terms of disability and premature mortality. Additionally, it was estimated that 63.5% of infections caused by antibiotic-resistant bacteria are associated with healthcare settings.

As the global population ages, the number of individuals with chronic conditions such as diabetes, cancer, and cardiovascular diseases increases. These patients often require long-term catheterization, which further amplifies the risks of CRBSIs. In addition, the growing prevalence of immunocompromised patients, including those undergoing chemotherapy or receiving organ transplants, also contributes to a higher rate of hospital-acquired infections. These patient populations are more susceptible to infections due to weakened immune systems, which increases the risk of bacterial or fungal pathogens entering through the catheter.

Healthcare-associated infections are a significant burden on healthcare systems worldwide. These infections are associated with extended hospital stays, higher treatment costs, and an increased risk of complications such as sepsis. This creates an urgent need for more effective infection control measures, including antimicrobial-coated catheters, new diagnostic technologies, and more stringent hygiene practices in hospitals. Healthcare institutions, recognizing the high morbidity and mortality associated with catheter-related bloodstream infections, are investing in new technologies and products to reduce the incidence of these infections.

Rising Demand for Advanced Diagnostic Technologies

The growing prevalence of catheter-related bloodstream infections has highlighted the urgent need for improved diagnostic tools. Early and accurate detection is crucial to preventing the escalation of these infections, as prompt intervention significantly reduces the risk of severe complications and death. This has led to an increasing demand for advanced diagnostic technologies that can quickly identify pathogens in the bloodstream, even in cases where the infection may not be immediately obvious. Traditional diagnostic methods, such as blood cultures, are time-consuming and may take up to 48 hours to provide results. In contrast, newer diagnostic technologies, such as molecular diagnostics, PCR (polymerase chain reaction) assays, and real-time microbial identification systems, offer faster and more accurate detection, providing results within hours. In November 2024, Citius Pharmaceuticals, Inc. announced that it recently held a productive in-person Type C meeting with the U.S. Food and Drug Administration (FDA). This meeting followed the successful completion of the Company’s pivotal Phase 3 clinical trial of Mino-Lok®, an innovative catheter lock solution designed to preserve central venous catheters in patients with central line-associated bloodstream infections (CLABSI) or catheter-related bloodstream infections (CRBSI). The main focus of the discussion was addressing the FDA’s questions regarding Mino-Lok’s clinical trial data and exploring the pathway for future submission.

These advancements in diagnostic technology are helping clinicians detect infections earlier, enabling more targeted treatment plans that can improve patient outcomes. The development of point-of-care diagnostics, which allow rapid testing at the patient’s bedside, is a particularly significant trend in the healthcare sector. Point-of-care devices can detect pathogens with high sensitivity and specificity, which is essential for diagnosing catheter-related bloodstream infections. These devices offer the advantage of reducing the time and resources required for testing, making them particularly valuable in critical care environments, such as intensive care units.

The rising demand for rapid and accurate diagnostic tests also stems from the need to combat antibiotic resistance. Inappropriate or delayed antibiotic use is a significant concern in the treatment of catheter-related bloodstream infections, as it can contribute to the emergence of resistant pathogens. Rapid diagnostics can guide clinicians in choosing the right antibiotic, reducing the risk of resistance development. These diagnostics can help identify specific pathogens causing the infection, enabling healthcare providers to prescribe more targeted treatments that are more effective and less likely to contribute to resistance.

Increase in the Use of Catheters in Medical Procedures

The increasing use of central venous catheters in various medical procedures is a key factor driving the growth of the global catheter-related bloodstream infection market. As medical technologies and treatments evolve, more patients require invasive procedures that involve the use of catheters. Central venous catheters are commonly used in intensive care units, surgeries, cancer treatments, and for patients who require long-term intravenous access. These procedures often involve the insertion of catheters into major blood vessels, which, while crucial for patient care, also carry the risk of introducing harmful pathogens into the bloodstream, leading to catheter-related bloodstream infections. The higher volume of procedures involving catheter insertion directly increases the risk of infection and necessitates the development of better infection prevention strategies, diagnostic tools, and treatment options, thus expanding the market for these solutions.

Rising Healthcare Costs and Economic Burden of Infections

Catheter-related bloodstream infections not only lead to significant morbidity and mortality but also impose a substantial economic burden on healthcare systems. The costs associated with treating these infections include longer hospital stays, additional diagnostic testing, prolonged antibiotic therapy, and more complex care. In severe cases, patients may require surgical interventions, which further contribute to the financial strain. According to a study, “Incidence and determinants of nosocomial infection among hospital admitted adult chronic disease patients in University of Gondar Comprehensive Specialized Hospital, North–West Ethiopia, 2016–2020”, a total of 597 adult chronic illness patients (99.6%) were included in the study. Among them, 53 participants (8.88%) developed nosocomial infections, resulting in an incidence rate of 6.6 per 1,000 person-days of observation. The study found several factors significantly associated with nosocomial infections, including not taking antibiotics (AHR = 2.74, 95% CI: 1.49, 5.04), using mechanical ventilation (AHR = 2.67, 95% CI: 1.36, 5.26), having a urinary catheter (AHR = 4.62, 95% CI: 2.22, 9.65), being on an intravenous catheter (AHR = 3.42, 95% CI: 1.22, 9.61), and a hospital stay longer than 20 days (AHR = 2.66, 95% CI: 1.43, 4.94).

The economic burden of these infections is driving healthcare providers to seek more efficient and cost-effective solutions to prevent and treat catheter-related bloodstream infections. As a result, there is a growing demand for products and technologies that can reduce infection rates, shorten hospital stays, and improve overall healthcare efficiency, thereby helping to reduce the financial impact of these infections on hospitals and health systems.

Expanding Healthcare Infrastructure in Emerging Markets

The expansion of healthcare infrastructure in emerging markets is also contributing to the growth of the global catheter-related bloodstream infection market. As countries in regions such as Asia-Pacific, South America, and the Middle East invest in improving healthcare systems and access to medical services, there is an increased need for medical devices, including catheters. The rising number of patients requiring catheter-based procedures in these regions increases the risk of infections, prompting the demand for infection prevention products and technologies. The growing awareness of the importance of infection control in these markets, supported by international health organizations, is encouraging healthcare providers to adopt advanced technologies aimed at reducing the incidence of catheter-related bloodstream infections. This expansion in emerging markets presents significant opportunities for growth in the global market.

Download Free Sample Report

Key Market Challenges

High Cost of Advanced Infection Prevention Technologies

One of the significant challenges in the global Catheter Related Bloodstream Infection market is the high cost of advanced infection prevention technologies. While innovative solutions such as antimicrobial-coated catheters, rapid diagnostic tools, and biofilm-resistant materials have proven effective in reducing infection rates, these technologies often come with a premium price. This cost barrier can be a challenge, especially in low-resource healthcare settings or emerging markets where budget constraints are a significant concern. Hospitals and healthcare providers may be hesitant to adopt these advanced solutions if they face financial limitations, despite the long-term benefits in terms of improved patient outcomes and reduced healthcare costs. The cost of training healthcare staff to effectively use these advanced technologies and maintain infection control protocols further compounds the financial burden on healthcare systems, making it difficult for some institutions to fully embrace these innovations.

Risk of Antibiotic Resistance

Antibiotic resistance remains a significant challenge in the treatment of catheter-related bloodstream infections. The overuse and misuse of antibiotics, both in hospital settings and in the community, have led to the emergence of drug-resistant bacteria, complicating treatment regimens for infections. As more pathogens become resistant to commonly used antibiotics, treating CRBSIs becomes more difficult, requiring stronger, more expensive, and often more toxic medications. This creates a vicious cycle, where the use of stronger antibiotics further contributes to resistance, leading to more complicated infections. Despite advances in diagnostic technologies, the growing prevalence of antibiotic-resistant bacteria continues to be a major challenge in managing catheter-related bloodstream infections, underscoring the need for more effective infection prevention strategies and novel antimicrobial treatments.

Inconsistent Adoption of Infection Control Protocols

While infection control guidelines are becoming more widely recognized, there is still inconsistency in their adoption across healthcare settings. The implementation of standardized infection control protocols, such as proper catheter insertion techniques, routine monitoring, and sterilization practices, can vary greatly depending on the hospital or healthcare facility. In some cases, hospitals may struggle with a lack of resources or staff training, which leads to poor adherence to best practices, increasing the risk of catheter-related bloodstream infections. Healthcare workers may experience "protocol fatigue," leading to a decline in compliance over time. This inconsistency in following infection control measures remains a significant barrier to reducing the incidence of CRBSIs, even when preventive technologies are available.

Key Market Trends

Technological Advancements in Catheter Materials

Innovations in catheter design and material science are also contributing to the growth of the catheter-related bloodstream infection market. One significant development has been the introduction of antimicrobial-coated catheters, which are designed to reduce the risk of infection by inhibiting the growth of bacteria and other pathogens on the surface of the catheter. These catheters have been shown to significantly decrease the incidence of catheter-related bloodstream infections, especially in high-risk patient populations. In January 2025, Autonomix Medical, Inc. announced that it has achieved "design lock" for its Application Specific Integrated Circuits (ASIC) microchip. This milestone follows the successful completion of in vivo preclinical testing and extensive bench testing, marking continued progress toward the Company's U.S. pivotal trial.

The development of biofilm-resistant materials, which prevent the formation of bacterial biofilms on catheter surfaces, is further enhancing the safety and efficacy of catheters. As these technologies continue to advance, the demand for these more sophisticated catheter products is likely to grow, driving market expansion.

Growing Adoption of Infection Control Guidelines

The growing global emphasis on infection control measures has significantly contributed to the expansion of the catheter-related bloodstream infection market. In response to the rising incidence of hospital-acquired infections, healthcare organizations worldwide have developed and implemented infection control guidelines and protocols to reduce the risk of catheter-related bloodstream infections. These guidelines emphasize the importance of sterile techniques during catheter insertion, routine monitoring of catheter sites, the use of antimicrobial dressings, and timely catheter removal when no longer necessary. Healthcare providers are increasingly adopting these guidelines to improve patient outcomes and reduce infection rates, driving the demand for products and services that support infection prevention efforts. The widespread adoption of infection control protocols is expected to continue to promote the growth of the catheter-related bloodstream infection market.

Segmental Insights

Distribution Channel Insights

Based on the Distribution Channel segment, hospital pharmacies was dominating the global catheter-related bloodstream infection market. The dominance of hospital pharmacies in this market can be attributed to several factors, particularly their central role in the management of critical care patients, who are most at risk of developing CRBSIs. Hospital pharmacies are integral to healthcare systems, especially in acute care settings such as intensive care units (ICUs), where patients frequently require invasive procedures, including catheter insertions. This patient population is at the highest risk for developing catheter-related infections due to the prolonged use of central venous catheters and other types of invasive devices.

Hospital pharmacies are directly involved in the procurement, preparation, and dispensing of medications specifically tailored for hospitalized patients, including those undergoing treatments for CRBSIs. These medications often include broad-spectrum antibiotics, antifungal agents, and antiseptic solutions that are used both prophylactically and therapeutically to manage catheter-related infections. Hospital pharmacies also oversee the administration of antibiotics via intravenous routes and the implementation of antibiotic lock therapy, which is a critical method for preventing and treating CRBSIs. This specialized care, tailored to individual patient needs, requires a deep understanding of infection control protocols, which hospital pharmacies are uniquely positioned to provide.

Hospital pharmacies are the primary point of contact for patients with complex and critical conditions, including those with immune deficiencies, chronic illnesses, or those undergoing major surgeries, all of which increase the likelihood of catheter-related bloodstream infections. Given that hospital pharmacies cater to high-risk populations, the demand for anti-microbial agents, infection prevention products, and treatment options is higher in these settings, contributing to the dominance of hospital pharmacies in the CRBSI market. In addition to their role in providing medications, hospital pharmacies also play a key role in infection management through the implementation of infection control protocols, the selection of appropriate therapies based on diagnostic tests, and the monitoring of patient responses to treatment. The close collaboration between hospital pharmacists, healthcare providers, and infection control teams ensures that patients at risk of CRBSIs receive timely and effective treatment. This integrated approach to patient care is critical for managing infections and preventing complications in hospitalized patients, further strengthening the role of hospital pharmacies in the CRBSI market.

Download Free Sample Report

Regional Insights

North America was dominating the Global Catheter Related Bloodstream Infection Market. Several factors contribute to North America's leadership in this market, primarily the advanced healthcare infrastructure, high prevalence of healthcare-associated infections, and robust healthcare spending in the region. The United States, in particular, plays a crucial role in driving the market due to its well-established healthcare system, the widespread use of catheters in medical procedures, and the high rate of chronic diseases that require prolonged catheterization, such as kidney failure and cancer. The region's healthcare facilities, particularly hospitals and intensive care units (ICUs), frequently perform invasive procedures that increase the risk of catheter-related bloodstream infections, further contributing to the market’s growth.

The healthcare system in North America is one of the most advanced globally, with cutting-edge technologies and highly skilled professionals in the field of infection prevention and treatment. Hospitals in this region are equipped with state-of-the-art diagnostic and therapeutic technologies that are essential for managing and treating CRBSIs. As a result, the demand for anti-microbial agents, diagnostic tests, and infection prevention products is particularly high, positioning North America as a dominant region in the market.

Another significant factor driving the growth of the Global Catheter Related Bloodstream Infection Market in North America is the increasing focus on patient safety and the prevention of healthcare-associated infections. The region has implemented stringent infection control protocols and guidelines that emphasize the prevention of catheter-related bloodstream infections. For instance, hospitals and healthcare providers across the U.S. and Canada have adopted comprehensive infection prevention strategies, including the use of antimicrobial-coated catheters and the implementation of antibiotic stewardship programs. These efforts are helping to reduce the incidence of CRBSIs, but they also drive the demand for innovative solutions in the market, ensuring that North America remains a key player in the global landscape.

Recent Developments

• In October 2023, TekniPlex introduced thermoplastic elastomer (TPE) and polyvinyl chloride (PVC) compounds enhanced with silver ion technology, designed for the treatment of CRBSI. To create its antimicrobial product line, TekniPlex Healthcare combines its extensive range of medical-grade flexible and rigid PVC compounds, or its medical-grade CELLENE® TPE compounds, with silver ions, which possess natural antibacterial properties. Unlike disinfectants that lose effectiveness over time, medical products made with antimicrobial compounds offer continuous protection throughout the product's lifespan.
• In December 2023, researchers at Texas A&M University (College Station, TX, USA) began developing an innovative catheter dressing aimed at reducing the incidence and severity of bloodstream infections associated with catheter use. This advanced dressing will include wireless sensors capable of detecting even trace amounts of bacterial growth on the skin, in combination with the catheter.
• In November 2023, the FDA approved the DefenCath® catheter lock solution for use with central venous catheters (CVC) in adult patients undergoing chronic hemodialysis due to renal failure, aiming to reduce the incidence of CRBSI in this patient group. DefenCath combines taurolidine, an antibacterial thiadiazinane, with heparin, an anticoagulant. Taurolidine has been shown to be effective against a wide range of bacteria, contributing to the solution’s ability to prevent infections associated with CVC use.
• In September 2024, Shockwave Medical, now a part of Johnson & Johnson MedTech, officially launched its Shockwave E8 Peripheral IVL Catheter in the United States. Recently, Johnson & Johnson acquired the intravascular lithotripsy (IVL) company for approximately USD 13 billion. While many of Johnson & Johnson's acquisitions have been rebranded under the Johnson & Johnson MedTech name, Shockwave remains under its original brand for the time being.

Key Market Players

• Teva Pharmaceutical Industries Ltd.
• SteriMax Inc.
• Sanofi S.A.
• Pfizer Inc.
• Novartis AG
• Merck & Co., Inc.
• GSK plc
• Fresenius SE & Co. KGaA
• Eli Lilly and Company
• Aurobindo Pharma Limited

Report Scope:

In this report, the Global Catheter Related Bloodstream Infection Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Catheter Related Bloodstream Infection Market, By Treatment Type:

o   Anti-microbial Agents

o   Antibiotic Lock Therapy

• Catheter Related Bloodstream Infection Market, By Source of Infection:

o   Coagulase-negative Staphylococcus

o   S. Aureus

o   Enteric Gram-negative Bacilli

o   Yeasts

o   Enterococci & Streptococci

o   Pseudomonas

o   Others

• Catheter Related Bloodstream Infection Market, By Distribution Channel:

o   Hospital Pharmacies

o   Retail Pharmacies

o   Online Pharmacies

• Catheter Related Bloodstream Infection Market, By Region:

o   North America

§  United States

§  Canada

§  Mexico

o   Europe

§  France

§  United Kingdom

§  Italy

§  Germany

§  Spain

o   Asia-Pacific

§  China

§  India

§  Japan

§  Australia

§  South Korea

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Catheter Related Bloodstream Infection Market.

Available Customizations:

Global Catheter Related Bloodstream Infection market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).